Reviews to Results: How Inspire TMS Tracks Patient Outcomes

Patients tell us the same thing again and again in reviews: they want clear evidence that treatment is working. At Inspire TMS Denver, we take that request literally - we don’t rely on impressions alone. We measure, record, and act on standardized outcome scores (like the PHQ-9) so every treatment decision is informed by data. That’s why our clinic reviews - the patient stories and high ratings you see online - are paired with hard numbers in our records: we translate “I feel better” into measurable change, and we use those numbers to shape treatment, follow-up, and long-term care.
Why measurement matters
TMS is powerful because it changes brain circuits. But brain change doesn’t always track neatly with how someone says they feel, especially early in treatment. Standardized scales give clinicians a consistent, sensitive way to detect meaningful clinical change, monitor safety, and decide whether to continue, adjust, or remap a course.
At Inspire, we routinely use validated tools (most commonly the PHQ-9 for depression, and condition-specific measures where appropriate) before treatment, during the course, and at follow-up. These measures let us answer the crucial questions:
- Is the patient improving, and by how much?
- Is the current protocol producing the expected signal?
- Do we need to remap, change pacing, or offer a maintenance/rescue plan?
Collecting and reviewing scores is not paperwork - it is how we turn patient experience into reproducible clinical decisions.
What your scores actually mean (PHQ-9 primer)
A few PHQ-9 facts are useful for patients:
- PHQ-9 range: 0–27. Lower is better.
- Common interpretive bands: 0–4 (minimal), 5–9 (mild), 10–14 (moderate), 15–19 (moderately severe), 20–27 (severe).
- Clinical response is often defined as a
≥50% reduction in PHQ-9 score from baseline;
remission is typically a score in the minimal or near-minimal range.
These guidelines let clinicians quantify improvement and compare progress across visits. Research and clinic reports commonly show robust response and remission rates when TMS is delivered to completion - published and clinic-level data often cite response rates in the 60–75% range and remission rates approaching ~45–51% among full-course completers. Those benchmarks help us set realistic expectations and evaluate our own results.
How Inspire uses scores day-to-day
Here’s how outcome tracking informs care at Inspire:
Baseline & goals. We collect a baseline PHQ-9 (and other relevant scales). Dr. Clinch and the team set realistic targets and timelines — e.g., a 50% score reduction by week 4–6 — and share those with the patient.
Frequent measurement. We repeat scores at scheduled intervals during treatment (weekly or at clinically meaningful points) so we can detect early signals that predict longer-term response.
Data-driven adjustments. If scores plateau or worsen, we don’t guess - we review: does mapping need refinement? Is a medication interaction or a sleep problem present? Should we change protocol pacing, remap, or consider a rescue/maintenance plan? Remapping or protocol changes are common, evidence-driven steps when the data suggest they’re needed.
Shared results & transparency. We show patients their numbers over time so they can see the progress (or lack of it) and participate in decisions. This transparency is part of why many patients report a better experience at Inspire - they understand how clinical choices are made and why.
Outcome scores and patient reviews - how they match up
Patient reviews are invaluable: they capture nuance, meaning, and quality of experience. But reviews are subjective and influenced by many non-clinical factors (appointment flow, staff warmth, travel ease). Outcome tracking gives a reproducible, objective counterpart.
At Inspire, we regularly compare patient-reported outcomes with review themes. When a patient posts a high-rating review that mentions life improvements, we can show the corresponding PHQ-9 change in the record. Conversely, when review feedback suggests a problem (e.g., persistent symptoms or side effects), our scores often highlight the clinical trajectory that underlies that feedback. This two-way verification - reviews and scores - helps us continuously improve care and confirms that good experience usually follows measurable clinical benefit.

Download Your Roadmap to TMS
Want a clear picture of what to expect? Download the TMS Treatment Roadmap by Sydney
Examples
- Patient A: Baseline PHQ-9 20 → week 4 PHQ-9 9 (≥50% reduction). Patient reported “night-and-day” difference in mood and resumed work activities. This objective drop matched the glowing review they later posted.
- Patient B: Baseline PHQ-9 17 → week 3 PHQ-9 15 (minimal change). We remapped and adjusted pacing; by week 6, PHQ-9 was 8, and the patient reported marked functional gains.
Fast clinical measurement → informed adjustment → better results. Remapping and protocol tweaks are not failures - they’re precision medicine in action.
Beyond PHQ-9 - broader outcome tracking
While PHQ-9 is central for depression, we also track condition-specific scales (GAD-7 for anxiety, OCD scales when relevant), functional measures (work/school participation), and patient satisfaction. All of these feed into a single clinical dashboard that Dr. Clinch reviews - it gives a 360° view of how the patient is doing and what’s needed next. Standardized tracking also enables Inspire to report clinic-level outcomes and refine protocols over time.
What does measurement mean for you as a patient?
- You’ll know early whether treatment is working. Objective scores detect change sooner than impressions alone.
- Your care will be responsive. If numbers don’t improve, the team won’t wait - they’ll remap, re-dose, or change protocol.
- Your review matters - but so do the numbers. We want you to feel better and to be able to show it with data. Many of our highest-rated reviews reflect that measurable improvement.
How often will I take the PHQ-9?
Typically at baseline, weekly during treatment blocks, at end of course, and during follow-up. Frequency may be adjusted to the clinical plan.
What counts as a “response” or “remission”?
A common clinical standard is ≥50% reduction from baseline for response; remission is often defined as a PHQ-9 in the minimal range (e.g., ≤4). These thresholds guide clinical decisions.
What if my scores don’t improve?
We review mapping, medications, sleep, and adherence; we may remap, adjust pacing/intensity, or consider maintenance/rescue strategies. Remapping and protocol adjustments are routine and evidence-based.

Every Question Answered
Want to know more about TMS? Check out this in-depth guide to TMS therapy with transparent and easy to understand explanations about TMS processes, protocols, and treated conditions.
Latest Posts

















